Meeting report of the 4th biennial Metabolism and Cancer symposium.
cancer
epigenetics
hypoxia
metabolism
mitochondria
redox
signaling
Journal
The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
18
11
2021
received:
05
10
2021
accepted:
23
11
2021
pubmed:
25
11
2021
medline:
23
9
2022
entrez:
24
11
2021
Statut:
ppublish
Résumé
The 4th International meeting Metabolism and Cancer initially programed to take place in Bordeaux (France) was held virtually on May 27-29, 2021. The three-day event was followed by around 600 participants daily from 47 countries around the world. The meeting hosted 21 speakers including selected talks and a keynote lecture from the Nobel Prize winner Sir Peter J. Ratcliffe (Oxford, UK). Presentations and discussions were divided in four scientific sessions: (a) Redox and energy metabolism (b) Redox and hypoxia (c) Metabolic profiling and epigenetic control and (d) Signalling, fuelling and metabolism in cancer and a general public session on cancer and nutrition. This report summarises the presentations and outcomes of the 4th annual Metabolism and Cancer symposium. We provide here a summary of the scientific highlights of this exciting meeting.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5516-5526Informations de copyright
© 2021 Federation of European Biochemical Societies.
Références
Chouchani ET, Pell VR, Gaude E, Aksentijević D, Sundier SY, Robb EL, Logan A, Nadtochiy SM, Ord ENJ, Smith AC et al. (2014) Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 515, 431-435.
Chouchani ET, Pell VR, James AM, Work LM, Saeb-Parsy K, Frezza C, Krieg T & Murphy MP (2016) A unifying mechanism for mitochondrial superoxide production during ischemia-reperfusion injury. Cell Metab 23, 254-263.
Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE, Tourlomousis P, Däbritz JHM, Gottlieb E, Latorre I et al. (2016) Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell 167, 457-470.e13.
Yin Z, Burger N, Kula-Alwar D, Aksentijević D, Bridges HR, Prag HA, Grba DN, Viscomi C, James AM, Mottahedin A et al. (2021) Structural basis for a complex I mutation that blocks pathological ROS production. Nat Commun 12, 707.
Daher B, Parks SK, Durivault J, Cormerais Y, Baidarjad H, Tambutte E, Pouysségur J & Vučetić M (2019) Genetic ablation of the cystine transporter xCT in PDAC cells inhibits mTORC1, growth, survival, and tumor formation via nutrient and oxidative stresses. Can Res 79, 3877-3890.
Meira W, Daher B, Parks SK, Cormerais Y, Durivault J, Tambutte E, Pouyssegur J & Vučetić M (2021) A cystine-cysteine intercellular shuttle prevents ferroptosis in xCT(KO) pancreatic ductal adenocarcinoma cells. Cancers 13.
Porporato PE, Payen VL, Pérez-Escuredo J, De Saedeleer CJ, Danhier P, Copetti T, Dhup S, Tardy M, Vazeille T, Bouzin C et al. (2014) A mitochondrial switch promotes tumor metastasis. Cell Rep 8, 754-766.
Masoud R, Reyes-Castellanos G, Lac S, Garcia J, Dou S, Shintu L, Abdel Hadi N, Gicquel T, El Kaoutari A, Diémé B et al. (2020) Targeting mitochondrial complex I overcomes chemoresistance in high OXPHOS pancreatic cancer. Cell Rep Med 1, 100143.
Ratcliffe PJ, O'Rourke JF, Maxwell PH & Pugh CW (1998) Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 201, 1153-1162.
Chowdhury R, Leung IK, Tian YM, Abboud MI, Ge W, Domene C, Cantrelle FX, Landrieu I, Hardy AP, Pugh CW et al. (2016) Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases. Nat Commun 7, 12673.
Kaelin WG Jr & Ratcliffe PJ (2008) Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30, 393-402.
Loreti E, van Veen H & Perata P (2016) Plant responses to flooding stress. Curr Opin Plant Biol 33, 64-71.
Masson N, Keeley TP, Giuntoli B, White MD, Puerta ML, Perata P, Hopkinson RJ, Flashman E, Licausi F & Ratcliffe PJ (2019) Conserved N-terminal cysteine dioxygenases transduce responses to hypoxia in animals and plants. Science 365, 65-69.
Wykoff CC, Pugh CW, Maxwell PH, Harris AL & Ratcliffe PJ (2000) Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19, 6297-6305.
Pugh CW & Ratcliffe PJ (2017) New horizons in hypoxia signaling pathways. Exp Cell Res 356, 116-121.
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921.
Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, Lakshman M, Gottipati P, Oliver FJ, Helleday T et al. (2010) Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Can Res 70, 8045-8054.
Chiappa M, Guffanti F, Bertoni F, Colombo I & Damia G (2021) Overcoming PARPi resistance: preclinical and clinical evidence in ovarian cancer. Drug Resist Updat 55, 100744.
Mehibel M, Xu Y, Li CG, Moon EJ, Thakkar KN, Diep AN, Kim RK, Bloomstein JD, Xiao Y, Bacal J et al. (2021) Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. J Clin Investig 131, e146256.
Tusa I, Cheloni G, Poteti M, Silvano A, Tubita A, Lombardi Z, Gozzini A, Caporale R, Scappini B, Dello Sbarba P et al. (2020) In vitro comparison of the effects of imatinib and ponatinib on chronic myeloid leukemia progenitor/stem cell features. Target Oncol 15, 659-671.
Giuntoli S, Tanturli M, Di Gesualdo F, Barbetti V, Rovida E & Dello Sbarba P (2011) Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate. Haematologica 96, 204-212.
Bono S, Lulli M, D'Agostino VG, Di Gesualdo F, Loffredo R, Cipolleschi MG, Provenzani A, Rovida E & Dello Sbarba P (2016) Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction. Oncotarget 7, 84810-84825.
Morin A, Goncalves J, Moog S, Castro-Vega LJ, Job S, Buffet A, Fontenille MJ, Woszczyk J, Gimenez-Roqueplo AP, Letouzé E et al. (2020) TET-mediated hypermethylation primes SDH-deficient cells for HIF2α-driven mesenchymal transition. Cell Rep 30, 4551-4566.e7.
Shin S, Nicolle R, Jean C, Samain R, Ayadi M, Raffenne J, Brunel A, Solorzano J, Neuzillet C, Joffre C et al. (2021) Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer. Pancreatology 21, S43.
Argüello RJ, Combes AJ, Char R, Gigan JP, Baaziz AI, Bousiquot E, Camosseto V, Samad B, Tsui J, Yan P et al. (2020) SCENITH: a flow cytometry-based method to functionally profile energy metabolism with single-cell resolution. Cell Metab 32, 1063-1075.e7.
Giraud J, Chalopin D, Blanc JF & Saleh M (2021) Hepatocellular carcinoma immune landscape and the potential of immunotherapies. Front Immunol 12, 655697.
Kakimoto PA, Chausse B, Caldeira da Silva CC, Donato Júnior J & Kowaltowski AJ (2019) Resilient hepatic mitochondrial function and lack of iNOS dependence in diet-induced insulin resistance. PLoS One 14, e0211733.
Hanahan D & Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
Miceli C, Roccio F, Penalva-Mousset L, Burtin M, Leroy C, Nemazanyy I, Kuperwasser N, Pontoglio M, Friedlander G, Morel E et al. (2020) The primary cilium and lipophagy translate mechanical forces to direct metabolic adaptation of kidney epithelial cells. Nat Cell Biol 22, 1091-1102.
Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals M, Barneda D, Sellers K, Campos-Olivas R, Graña O et al. (2015) MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab 22, 590-605.
Tajan M, Hennequart M, Cheung EC, Zani F, Hock AK, Legrave N, Maddocks ODK, Ridgway RA, Athineos D, Suárez-Bonnet A et al. (2021) Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy. Nat Commun 12, 366.